[
    {
        "section": "For purposes of this Section 1.2, person means mean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a person as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated thereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government.",
        "explanation": "There is a typo in this definition. The phrase 'person means mean' should be corrected to 'person means'.",
        "location": "Section 1.2",
        "category": 5,
        "location_match": false,
        "text_match": false,
        "explanation_match": false
    },
    {
        "section": "1.68 Royalty Term means, with respect to a Product on a country-by-country basis, the period of time beginning on the First Commercial Sale of such Product in such country and ending the later of (i) the expiration of the last to expire Valid Claim Covering the Antibody or Product in such country, or (ii) [***] ([***]) years from the First Commercial Sale of such Product in such country. Notwithstanding subsections (i) and (ii) above, the Royalty Term for a Product in a country shall not [***].",
        "explanation": "This section states that the Royalty Term ends on the later of patent expiration or a certain number of years from first commercial sale, however, the last sentence indicates it shall not [***]. This creates an ambiguity.",
        "location": "Section 1.68",
        "category": 1,
        "location_match": false,
        "text_match": false,
        "explanation_match": false
    },
    {
        "section": "The accounting firm shall disclose to Xencor only whether the reports are correct or incorrect and the specific details concerning any discrepancies. No other information shall be provided to Xencor. The accounting firm shall provide Aimmune with a copy of any disclosures or reports made to Xencor and Aimmune shall have an opportunity to discuss such disclosures or reports with Xencor and the accounting firm. Information, disclosures, or reports arising from any such examination shall be Confidential Information of Aimmune subject to the confidentiality and other obligations of ARTICLE 12.",
        "explanation": "This section describes the process for the accounting firm to disclose if the reports are correct and provide Aimmune an opportunity to discuss the disclosures, the phrase that the information is confidential to Aimmune is misplaced. The information should be confidential to both parties.",
        "location": "Section 8.4",
        "category": 9,
        "location_match": false,
        "text_match": false,
        "explanation_match": false
    }
]